EndoTAG-1 MediGene

Current Opinion in Investigational Drugs

Volumn 6, Issue 12, 2005, Pages 1259-1265

  Schuch, Gunter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ALBUMIN; ANTINEOPLASTIC AGENT; ANX 510; BEVACIZUMAB; CHOLESTEROL; CILENGITIDE; COFACTOR; DIOLEOYLPHOSPHATIDYLCHOLINE; DOCOSAHEXAENOIC ACID; ENDOTAG 1; FATTY ACID; FLUOROURACIL; GEMCITABINE; LIPID; LIPOPAC; LIPOSOME; MACROGOL; MBT 0206; NANOPARTICLE; PACLITAXEL; PACLITAXEL DERIVATIVE; REAGENT; TAXOPREXIN; TOCOPHEROL DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ASTHENIA; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG MANUFACTURE; DRUG SCREENING; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG UPTAKE; ENCAPSULATION; FATIGUE; HUMAN; INFUSION REACTION; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; REVIEW; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIPOSOMES; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PANCREATIC NEOPLASMS;

EID: 29444441774     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. 58619 Taxol stabilizes microtubules in mouse fibroblast cells. Schiff PB, Horwitz SB PROC NATL ACAD SCI USA 1980 77 3 1561-1565
2. 175387 Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevitolia. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT J AM CHEM SOC 1971 93 9 2325-2327
3. 197619 Drug delivery systems: Water soluble taxol 2′-poly(ethylene glycol) ester prodrugs - design and in vivo effectiveness. Greenwald RB, Gilbert CW, Pendri A, Conover CD, Xia J, Martinez A J MED CHEM 1996 39 2 424-431
4. 476427 Clinical toxicities encountered with paclitaxel (Taxol). Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC SEMIN ONCOL 1993 4 Suppl 3 1-15
5. 480330 Munich Biotech starts further LipoPac trials. Munich Biotech AG PRESS RELEASE 2003 February 28
6. 480345 Munich Biotech AG initiates a phase Ib clinical trial on the treatment of gastrointestinal cancer with LipoPac. Munich Biotech AG PRESS RELEASE 2002 November 07
7. 480369 MBT Munich Biotechnology AG to start first clinical trial with new cancer drug LipoPac. MBT Munich Biotech GmbH PRESS RELEASE 2002 May 27
8. 511914 Munich Biotech announces positive results of its MBT-0206 phase I clinical trials among advanced solid tumor patients. Munich Biotech AG PRESS RELEASE 2003 November 06
9. 516558 Munich Biotech announces positive phase I results of MBT-0206 in metastatic breast cancer. Munich Biotech AG PRESS RELEASE 2003 December 08
10. 516559 Munich Biotech announces successful completion of a phase I study of MBT-0206 in combination with 5-FU in patients with advanced solid tumors. Munich Biotech AG PRESS RELEASE 2003 December 08
11. 516560 Munich Biotech announces the start of a clinical trial program of MBT-0206 as first line therapy in pancreatic cancer in combination with gemcitabine. Munich Biotech AG PRESS RELEASE 2003 December 08
12. 519472 Munich's cancer drug, MBT-0206, enters phase II trials. Munich Biotech AG PRESS RELEASE 2004 January 16
13. 530653 Dynamic magnet resonance tomography for monitoring the efficacy of an anti-vascular tumor therapy by paclitaxel encapsulating cationic lipid complexes (MBT-0206). Eichhorn ME, Becker S, Strieth S, Werner A, Sauer B, Ruhstorfer H, Michaelis U, Griebel J, Brix G, Jauch KW, Dellian M PROC AM ASSOC CANCER RES 2004 45 Abs 1310
14. 531496 MBT-0206 enhances the anti-tumor treatment in a highly metastatic human pancreatic cancer mouse model. Papyan A, Werner A, Ischenko I, Yezhelyev M, Teifel M, Michaelis U, Bruns CJ PROC AM ASSOC CANCER RES 2004 45 Abs 4104
15. 541911 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. Hurwitz H, Fehrenbache L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N et al N ENGL J MED 2004 350 23 2335-2342
16. 543816 Phase Ib study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic breast cancer. Bartelheim K, Ognerubov NA, Semiglazov VF, Vtoraya OM, Kaletta C, Reichenberger I, Michaelis U, Naujoks K, Clemens M PROC AM SOC CLIN ONCOL 2004 23 Abs 3079
17. 545534 Phase I study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic or advanced unresectable gastrointestinal cancer (GI cancer). Ridwelski K, Kettner E, Fahlke J, Bartelheim K, Hitzl M, Schulze B, Koeber R, Michaelis U, Naujoks K, Clemens MR PROC AM SOC CLIN ONCOL 2004 23 Abs 3163
18. 554566 MediGene acquires Munich Biotech's anticancer pipeline. MediGene AG PRESS RELEASE 2004 August 13
19. 599062 Phase I evaluation of paclitaxel poligiumex (PPX) administered weekly for patients with advanced cancer. Takimoto CH, Schwartz G, Romero O, Patnaik A, Tolcher A, Garrison M, Oldham FB, Bernareggi A, Rowinsky E PROC AM SOC CLIN ONCOL 2005 24 Abs 2043
20. 599066 Final results of a phase I study of liposome entrapped paclitaxel (LEP-ETU) in patients with advanced cancer. Damjanov M, Fishman MN, Steinberg JL, Fetterly GJ, Haas A, Grahn A, Lauay C, Dul JL, Sherman JW, Rubin EH PROC AM SOC CON ONCOL 2005 24 Abs 2048
21. 613453 Neovascular targeting chemotherapy: Encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Streith S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U, Dellian M INT J CANCER 2004 110 1 117-124
22. 613462 Neovascular targeting therapy: Paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M CLIN CANCER RES 2005 9 6 2335-2341
23. 613466 Intravenously-injected paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a humanized SCID mouse model. Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, Wolff K, Petzelbauer P ARCH DERMATOL RES 2003 294 10-11 Abs P157
24. 613479 Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a humanized SCID mouse model. Kuntsfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, Wolff K, Petzelbauer P J INVEST DERMATOL 2002 120 3 476-482
25. 619398 MediGene AG initiates clinical phase II trial of EndoTAG-1 in advanced pancreatic cancer. MediGene AG PRESS RELEASE 2005 August 24
26. 628721 Development of new taxane formulations. Haas H PHARM UNSERER ZEIT 2005 34 2 115-121
27. 628732 Phase I study of docosahexaenoic acid-paclitaxel: A taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Wolff AC, Donehower RC, Carducci MK, Carducci MA, Brahmer JR, Zabelina Y, Bradley MO, Anthony FH, Swindell CS, Witman PA, Webb NL, Baker SD CLIN CANCER RES 2003 9 10 Pt 1 3589-3597
28. 628780 Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: Preparation, characterization and pharmacokinetics. Dosio F, Arpicco S, Brusa P, Stella B, Cattel L J CONTROL RELEASE 2001 76 1-2 107-117
29. 628787 A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. Lundberg BB, Risovic V, Ramaswamy M, Wasan KM J CONTROL RELEASE 2003 86 1 93-100
30. 628820 Novel therapeutic nano-particles (lipocores): Trapping poorly water soluble compounds. Perkins WR, Ahmad I, Li X, Hirsh DJ, Masters GR, Fecko CJ, Lee J, Ali S, Nguyen J, Schupsky J, Herbert C et al INT J PHARM 2000 200 1 27-39
31. 628823 Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. Crosasso P, Ceruti M, Brusa P, Arpicco S, Dosio F, Cattel L J CONTROL RELEASE 2000 63 1-2 19-30
32. 628826 Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, McDonald DM J CON INVEST 1998 101 7 1401-1413
33. 628832 Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Krasnici S, Werner A, Eichhorn ME, Schmitt-Sody M, Pahernik SA, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M INT J CANCER 2003 105 4 561-567
34. 629471 A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S et al J NATL CANCER INST 2003 95 17 1320-1329
35. 629472 Paclitaxel and epirubicin versus paclitaxell and carboplatin as first-line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Fountzilas G, Kalofonos HP, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P, Kalogera-Fountzila A, Gogas H, Aravantinos G, Moulopoulos LA, Economopoulos T et al ANN ONCOL 2004 15 10 1517-1526
36. 629475 Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: A limited-access study - CALGB 9534. Akerley W, Herndon JE Jr, Lyss AP, Choy H, Turrisi A, Graziano S, Williams T, Zhang C, Vokes EE, Green MR CLIN LUNG CANCER 2005 7 1 47-53
37. 629477 Synthesis and HSA binding characterisation of the water soluble 7-succinyl paclitaxel. Battaglia A, Bertucci C, Bombardelli E, Cimitan S, Guerrini A, Morazzoni P, Riva A EUR J MED CHEM 2003 38 4 383-389
38. 629482 Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: In vitro and in vivo studies. Rodrigues DG, Maria DA, Fernandes DC, Valcluga CJ, Couto RD, Ibanez OC, Maranhao RC CANCER CHEMOTHER PHARMACOL 2005 55 6 565-576
39. 629483 Tocol emulsions for drug solubilization and parenteral delivery. Constantinides PP, Tustian A, Kessler DR ADV DRUG DELIV REV 2004 56 9 1243-1255
40. 630589 Taxol reactions. Price KS, Castells MC ALLERGY ASTHMA PROC 2002 23 3 205-208
41. 631271 Biotechnology - MediGene. Fuchs P DZ BANK AG ANALYST REPORT 2005 April 05 1-14